清脆的
基因组编辑
Cas9
计算生物学
生物
药物发现
转录激活物样效应核酸酶
功能基因组学
精密医学
基因组工程
药物开发
基因组学
基因组
遗传学
基因
生物信息学
药品
药理学
作者
Zuber Khan,Mumtaz,Sumedha Gupta,Sidharth Mehan,Tarun Sharma,Manjeet Kumar,Pankaj Kumar Maurya,Arun Kumar Sharma,Ghanshyam Das Gupta,Acharan S. Narula
标识
DOI:10.2174/0115665232376648250312050239
摘要
CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats) is a groundbreaking gene-editing technology that enables scientists to make precise changes to the DNA of living organisms. It was first discovered in Escherichia coli and emerged as a breakthrough tool in molecular biology. This technique is essential because of its adaptability, affordability, and ease of use. It uses the adaptive immune response of bacteria and archaea to repel viral invasions. It significantly influences drug discovery, functional genomics, disease models, and pharmaceutical research. CRISPR-Cas9 is a better and more accurate way to change genes than other methods, such as zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs). This technology promotes the generation of double-strand breaks in DNA, allowing for precise genetic alterations required for therapeutic target identification and confirmation. Functional genomics enables high-throughput screening (HTS) to identify gene functions, disease causes, and therapeutic targets. CRISPR-Cas9 increases drug development by enabling Cas9 to create novel antimicrobial drugs and cancer therapies. It has also helped to generate disease models, advance our understanding of neurodegenerative and other diseases, test a variety of chemicals, and facilitate precise genetic changes. Despite its promise, ethical considerations and the possibility of off-target effects require careful evaluation to ensure its safe and effective clinical application. This study investigates the current and future possibilities of CRISPR-Cas9 in drug development, focusing on its transformational influence and addressing the challenges and limitations of its therapeutic application.
科研通智能强力驱动
Strongly Powered by AbleSci AI